The Canadian market for fertility services saw significant growth after the introduction of in vitro fertilization (IVF) in the 1980s, representing an important change in reproductive health care. Initially, this service was part of a publicly funded health system, but assisted reproductive technologies (ART) gradually moved towards a mixed model where private clinics started to support public services to address increasing demand and widen options. This combination provided more opportunities for innovation and access, but it also created gaps in affordability and regional service availability. The progress of IVF and donor services in Canada has historically been influenced by intricate ethical discussions and regulatory limitations, especially regarding embryo management, third-party reproduction, and the commercialization of reproductive materials. These issues contributed to the implementation of the Assisted Human Reproduction Act (2004), which established specific regulations regarding donor anonymity, compensation, and clinical procedures. ART technically includes methods like IVF, intracytoplasmic sperm injection (ICSI), gamete donation, and embryo transfer, each with unique effects on patient results, genetic lineage, and long-term health tracking.

In practical terms, ART has allowed many Canadians to become parents despite issues related to health or age, while also leading to concerns over fair access, data visibility, and psychological effects. Canadian clinics have progressively put money into research and development to enhance success rates and improve procedure effectiveness. Cryopreservation methods, particularly vitrification, have advanced the storage of embryos and gametes, allowing for adaptable treatment schedules and preservation of fertility. Recently, tools that incorporate AI have started to change how embryos are selected, how sperm shapes are analyzed, and how cycles are optimized, providing precision driven by data that supports clinical choices. These advancements position Canada favorably in the world of fertility services, although continuous examination regarding regulations, ethics, and the balance between public and private sectors is crucial to its growth.According to the research report, "Canada Fertility Service Market Research Report, 2030," published by Actual Market Research, the Canada Fertility Service market is anticipated to add to USD 860 Million by 2025–30.This growth is influenced by increasing infertility rates, postponement of parenthood, and improved access to assisted reproductive technologies (ART). A significant recent change is the introduction of publicly funded IVF programs in several provinces, like British Columbia and Ontario, which provide a one-time funding of up to $19,000 contingent on income qualifications.

This shift in policy is transforming availability and cost, particularly for families with middle incomes. Prominent companies such as Trio Fertility, Olive Fertility Centre, and ReproMed play a central role in the market with diverse service offerings. Trio has one of the top success rates in Canada and focuses on recurring pregnancy loss programs and sophisticated IVF laboratories. Olive Fertility, which has clinics in British Columbia, highlights inclusive healthcare, offering services for donors, egg freezing, and pathways for LGBTQ+ family development. ReproMed, located in Toronto, is well-known for its expertise in third-party reproduction, which includes surrogacy, coordination of donors, and voluntary fertility preservation. Canada's strong reputation for delivering high-quality and reasonably priced care is drawing patients from the U.S., particularly those who are looking for more affordable IVF options or inclusive services that American insurance does not cover.

LGBTQ+ individuals and single parents also gain from specific programs and legal protections under the Assisted Human Reproduction Act, which disallows discrimination based on sexual orientation or marital status. Adherence to these regulations is overseen by the Canadian Fertility and Andrology Society (CFAS), which provides clinical guidelines on embryo transfer, donor screening, and ethical practices in third-party reproduction. Clinics are also required to comply with provincial health laws and Health Canada's regulations regarding donor safety and reimbursements. Canada's fertility market by cause of infertility is divided into Male Infertility and Female Infertility situation is changing quickly, with government funding driving an increase in IVF treatments especially those that use intracytoplasmic sperm injection (ICSI), which improves chances of fertilization in instances of male-factor infertility or previous IVF unsuccessful attempts. Provinces such as Ontario, Quebec, and British Columbia now provide publicly funded IVF cycles including ICSI for qualifying patients, making advanced assisted reproductive technology (ART) more available across different income levels. On the other hand, intrauterine insemination (IUI) continues to be a commonly chosen, economical option, often included in provincial plans with fewer criteria for eligibility and unlimited cycles in certain areas.

Public hospitals and some clinics still provide regular IVF without ICSI, especially for those with unexplained infertility or when using donor gametes, maintaining a focus on cost-effectiveness and straightforward clinical practices. At the same time, the demand for surrogacy is increasing significantly, particularly among LGBTQ+ families, single individuals choosing parenthood, and those with medical issues that prevent pregnancy. Canada's selfless surrogacy framework governed by the Assisted Human Reproduction Act guarantees legal clarity and ethical protections, while inclusive provincial policies and growing agency networks assist various family-building options. Fertility preservation initiatives are also becoming more popular, propelled by medical requirements (like cancer treatments), gender-affirming procedures, and the voluntary postponement of parenthood. Clinics now provide egg and sperm freezing through vitrification, frequently paired with provincial tax credits or reimbursement programs. These services are being increasingly woven into oncology, endocrinology, and transgender health pathways, showcasing a commitment to reproductive freedom.

Altogether, Canada's fertility ecosystem is evolving to be more inclusive, technologically advanced, and publicly financed although there are still regional differences and challenges with waitlists. Canada Fertility service by cause of infertility is divided into Male Infertility and Female Infertility. Female infertility continues to be the primary issue in Canada's reproductive health arena, with polycystic ovary syndrome (PCOS) and postponement of pregnancies standing out as major factors. PCOS impacts about 10-13% of women in Canada, frequently resulting in hormone imbalances, irregular ovulation, and increased infertility rates. Recent research indicates that women diagnosed with PCOS are more prone to giving birth at later ages and show higher levels of not having children compared to those without the syndrome. This pattern is further intensified by wider societal changes like focusing on careers, economic challenges, and delayed family formation which push attempts to conceive to older maternal ages, when fertility naturally diminishes.

Treatments such as ovulation induction and IVF are commonly utilized to address infertility linked to PCOS, although there is a growing emphasis on early detection and reproductive planning in medical recommendations. At the same time, male infertility is increasing, particularly in city areas, where lifestyle aspects such as stress, pollution, inactivity, and exposure to hormone disruptors are more prevalent. Conditions like non-obstructive azoospermia (NOA), characterized by significantly reduced sperm production, are receiving more attention, with Canadian scientists at UBC developing AI-driven tools and 3D bioprinting techniques to identify and potentially recreate viable sperm. These advancements are designed to help men facing infertility due to cancer therapies, genetic issues, or unknown causes. Male infertility now represents nearly half of the infertility cases among couples, yet it remains frequently under-identified and insufficiently discussed. The emotional impact on individuals and couples is considerable, leading to demands for more comprehensive and more openly addressed healthcare options.

Canada fertility service by end user is divided into Fertility Clinics, Hospitals, Surgical Centers and Clinical Research Institutes. Toronto and Vancouver serve as the main hubs for fertility services in Canada, featuring some of the most sophisticated and busiest clinics in the country. Establishments such as TRIO Fertility, CReATe Fertility Centre, and Olive Fertility Centre excel in successful outcomes, individualized care, and the use of advanced technologies like AI in embryo selection and time-lapse imaging. These metropolitan areas provide a wide range of services, including IVF, ICSI, donor coordination, and fertility preservation, often supported by funding from provincial sources and private financial options. Hospitals in Ontario and British Columbia are increasingly working together with fertility clinics to offer publicly funded IVF treatments, making access easier and decreasing wait times. For instance, Ontario’s Fertility Program backs over 50 clinics and hospital-linked centers, allowing for one funded IVF cycle per patient and unlimited IUI treatments.

Yet, there are few surgical centers that focus exclusively on fertility procedures, with most sophisticated practices like egg retrieval and embryo transfer consolidated within full-service clinics. This concentration creates challenges for patients residing in distant or underserved areas, typically necessitating travel to larger urban centers. In the research domain, institutions like McGill University and the University of British Columbia (UBC) are crucial in enhancing assisted reproductive technologies (ART). McGill’s multidisciplinary programs examine ethical considerations, reproductive rights, and sustainability within ART, while UBC researchers are at the forefront of AI-based diagnostic methods and gamete preservation strategies. These academic initiatives help shape clinical protocols and influence national discussions regarding equity, innovation, and reproductive freedom. Despite differences among regions, Canada’s fertility sector is characterized by strong partnerships between public and private entities, solid ethical regulations, and an increasing focus on inclusive, data-informed care.Considered in this report• Historic Year: 2019• Base year: 2024• Estimated year: 2025• Forecast year: 2030Aspects covered in this report• Fertility Services Market with its value and forecast along with its segments• Various drivers and challenges• On-going trends and developments• Top profiled companies• Strategic recommendationBy Procedure • IVF with ICSI• IUI• IVF without ICSI• Surrogacy• Others By Service • Fresh Non-Donor• Frozen Non-Donor• Egg and Embryo Banking• Fresh Donor• Frozen DonorBy Cause of Infertility • Male Infertility• Female InfertilityBy End User • Fertility Clinics• Hospitals• Surgical Centers• Clinical Research InstitutesConsidered in this report• Historic Year: 2019• Base year: 2024• Estimated year: 2025• Forecast year: 2030Aspects covered in this report• Fertility Services Market with its value and forecast along with its segments• Various drivers and challenges• On-going trends and developments• Top profiled companies• Strategic recommendationBy Procedure • IVF with ICSI• IUI• IVF without ICSI• Surrogacy• Others By Service • Fresh Non-Donor• Frozen Non-Donor• Egg and Embryo Banking• Fresh Donor• Frozen DonorBy Cause of Infertility • Male Infertility• Female InfertilityBy End User • Fertility Clinics• Hospitals• Surgical Centers• Clinical Research Institutes.